文献速递脑血管病

标准剂量替奈普酶对比低剂量阿替普酶治疗大血管闭塞性急性缺血性卒中:一项随机临床试验

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-01-01

本研究为日本多中心、随机、开放标签、优效性试验,纳入221例大血管闭塞且适合静脉溶栓后机械取栓的患者,比较标准剂量替奈普酶(0.25 mg/kg)与低剂量阿替普酶(0.6 mg/kg)。主要终点为初始血管造影的实质性再灌注,替奈普酶组10.3% vs 阿替普酶组3.6%,绝对差异6.5个百分点(90% CI 0.89-12.1),达到预设成功标准;90天功能结局和安全结局相似。

要点

  • 标准剂量替奈普酶(0.25 mg/kg)较日本常用的低剂量阿替普酶(0.6 mg/kg)提高早期实质性再灌注率。
  • 两组90天功能结局(共同优势比1.47,95% CI 0.92-2.35)及症状性颅内出血、死亡率相似。
  • 在低剂量阿替普酶为标准治疗地区,标准剂量替奈普酶是前景可期的溶栓选择。

核心结论

  • 标准剂量替奈普酶(0.25 mg/kg)在取栓前使用较低剂量阿替普酶(0.6 mg/kg)提高初始血管造影的早期实质性再灌注率,功能与安全结局相当。

研究设计与样本

  • 研究者发起的多中心、随机、对照、开放标签、优效性试验,2022年8月19日至2025年3月13日,随访3个月。
  • 共随机221例,218例接受试验药物纳入全分析集(替奈普酶107例;阿替普酶111例)。
  • 纳入大血管闭塞性卒中、症状发作4.5小时内适合静脉溶栓并后续机械取栓的患者。

主要发现

  • 主要终点实质性再灌注(mTICI 2b-3级或无可见血栓)替奈普酶组10.3% vs 阿替普酶组3.6%,绝对差异6.5个百分点(90% CI 0.89-12.1)。
  • 90天功能结局向更好方向偏移的估计共同优势比为1.47(95% CI 0.92-2.35)。
  • 症状性颅内出血替奈普酶组2.8% vs 阿替普酶组1.8%。
  • 90天死亡率替奈普酶组6.5% vs 阿替普酶组9.9%。

关键数值与推荐

  • 主要终点达到预设成功标准:实质性再灌注绝对差异6.5个百分点(90% CI 0.89-12.1)。
  • 替奈普酶剂量0.25 mg/kg,阿替普酶剂量0.6 mg/kg,均静脉给药。

临床怎么用

  • 在低剂量阿替普酶(0.6 mg/kg)为标准治疗地区,可考虑标准剂量替奈普酶(0.25 mg/kg)作为取栓前溶栓选择。
  • 替奈普酶早期再灌注率更高且安全性与低剂量阿替普酶相当,支持其在该人群中的潜在应用。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小(218例),功能结局置信区间较宽。
  • 结果主要适用于日本及采用低剂量阿替普酶为标准的亚洲地区人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tenecteplase has advantages over standard-dose alteplase for acute ischemic stroke. A low-dose alteplase regimen (0.6 mg/kg) remains the standard in Japan and is commonly used in several Asian countries. OBJECTIVE: To determine whether standard-dose tenecteplase at 0.25 mg/kg achieves a higher rate of recanalization on the initial angiogram than low-dose alteplase at 0.6 mg/kg in patients scheduled for mechanical thrombectomy. It is inevitable to generate evidence required to support potential regulatory approval of tenecteplase in Japan. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, multicenter, randomized, controlled, open-label, superiority trial was conducted from August 19, 2022, through March 13, 2025, with 3-month follow-up and was the first ever to compare tenecteplase (0.25 mg/kg) with alteplase (0.6 mg/kg) for acute ischemic stroke. Participants included patients with large-vessel-occlusion stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset followed by mechanical thrombectomy. A total of 221 patients were randomized and 218 who received trial drugs were included in the full analysis set (107 tenecteplase; 111 alteplase). These data were analyzed from July 2025 to December 2025. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive either intravenous tenecteplase or alteplase. MAIN OUTCOMES AND MEASURES: The primary outcome was substantial reperfusion (modified Treatment in Cerebral Ischemia grade 2b to 3 or no retrievable thrombus) on the initial angiogram. Secondary outcomes included the 90-day modified Rankin Scale. Safety outcomes were symptomatic intracranial hemorrhage within 24 to 36 hours and mortality at 90 days. RESULTS: A total of 218 patients (mean [SD] age, 77.1 [12.0] years; 92 female and 126 male) who received trial drugs were included in the full analysis set (107 tenecteplase; 111 alteplase). Substantial reperfusion occurred in 10.3% of the standard-dose tenecteplase group vs 3.6% of the low-dose alteplase group (absolute difference, 6.5 percentage points; 90% CI, 0.89-12.1), meeting the prespecified success criterion. The estimated common odds ratio for a shift toward better 90-day functional outcome with tenecteplase was 1.47 (95% CI, 0.92-2.35). Rates of symptomatic intracranial hemorrhage (2.8% vs 1.8%) and mortality (6.5% vs 9.9%) were similar between tenecteplase and alteplase groups. CONCLUSIONS AND RELEVANCE: In this study, standard-dose tenecteplase (0.25 mg/kg) prior to thrombectomy resulted in a higher rate of early substantial reperfusion compared with low-dose alteplase (0.6 mg/kg), with comparable functional and safety outcomes. Standard-dose tenecteplase is a promising thrombolytic option in regions where low-dose alteplase is currently the standard of care. TRIAL REGISTRATION: Japan Registry of Clinical Trials Identifier: 051210055.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Inoue M, Hirano T, Fukuda-Doi M, et al. Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42223935. doi:10.1001/jamaneurol.2026.1590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。